BMY - Mergers and acquisitions

Adds RYZ101, an IND Engine and Manufacturing Capability, to BMS Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ:RYZB). With the completion of the acquisition, RayzeBio shares have ceased trading on the NASDAQ Global Market and RayzeBio is now a wholly owned subsidiary of Bristol Myers Squibb. "We are excited to complete this transaction, which adds radiopharmaceutical therapeutics (RPTs), one of the fastest-growing new modalities for treating patients with solid tumors," said Chris Boerner, Ph.D., Chief Executive Officer, Bristol Myers Squibb. "By strengthening and further diversifying our oncology pipeline bey

The Acquisition, Via a Strategic Joint Venture with Healthpeak Properties, Further Accelerates Breakthrough's Growth in Premier Biotech Hubs SAN DIEGO, Calif., Jan. 10, 2024 /PRNewswire/ -- Breakthrough Properties ("Breakthrough"), a leading global life sciences real estate developer, today announced it has acquired a majority interest in Callan Ridge, a two-building Class A life science campus nearing completion in San Diego's preeminent Torrey Pines cluster. The 185,000-square-foot campus is fully leased to Turning Point Therapeutics, Inc., a subsidiary of Bristol-Myers Squibb Company (NYSE:BMY), through April 2035.

Bristol Myers Squibb (NYSE:BMY) announced today that it has successfully completed its acquisition of Turning Point Therapeutics, Inc. ("Turning Point"), in an all-cash transaction. With the completion of the acquisition, Turning Point shares have ceased trading on the NASDAQ Global Select Market and Turning Point is now a wholly owned subsidiary of Bristol Myers Squibb. "Turning Point has distinguished itself in the field of precision oncology, and this acquisition will further strengthen our leading oncology franchise," said Elizabeth Mily, Executive Vice President, Strategy & Business Development, Bristol Myers Squibb. "With Turning Point's lead asset, repotrectinib, Bristol Myers Squib

NEW YORK and SHANGHAI, Aug. 3, 2021 /PRNewswire/ -- WuXi STA – a subsidiary of WuXi AppTec –  today announced that it has completed the acquisition of a drug product manufacturing facility in Couvet, Switzerland from Bristol Myers Squibb (NYSE:BMY). WuXi STA first announced its plans to purchase the facility earlier this year. The acquisition will enhance WuXi STA's capabilities by adding capacity to support its global partners in bringing innovative medicines to patients around the world. The Couvet site is the first facility in Europe for WuXi STA. Opened in 2018, this facility's state-of-the-art tablet & capsule manufacturing and packaging capabilities will provide WuXi STA's customers m